Translational Research in Respiratory Diseases (RESP) Program

The Translational Research in Respiratory Diseases (RESP) Program builds upon the success of the Meakins-Christie Laboratories and the Respiratory Epidemiology and Clinical Research Unit (RECRU) to further bring together basic, clinical, population health and outcomes researchers in both adult and pediatric medicine.

The program is organized around four primary research themes: chronic airways disease, sleep-disordered breathing, neuromuscular dysfunction associated with respiratory disease, and pulmonary inflammation and infections.

RESP researchers recognize that an interdisciplinary approach is essential for understanding and ultimately better diagnosing as well as treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), sleep apnea, tuberculosis, cystic fibrosis and neurological or musculoskeletal diseases affecting the respiratory system.

Our researchers benefit from the state-of-the-art technology platforms available at the new RI-MUHC facilities, such as the Molecular Imaging and Histopathology Platforms, as well as being equally well-equipped to conduct high quality clinical trials and outcomes research through the Centre for Innovative Medicine and the Centre for Outcomes Research and Evaluation.

Review our research highlights and publications in the 2023 RI-MUHC Annual Report.

More selections: 20222021; 2020.

Explore the RESP Program

News and Events

Newspaper Icon

We are proud to celebrate the scientific achievements of our researchers and trainees in publications, grant competitions, honors and awards, and appointments, as well as in the mainstream press.

Calendar Icon

The RESP Program organizes and supports numerous speakers, seminars, and symposia throughout the year.

Research Initiatives

Researchers in the RESP program are involved in a multitude of research initiatives, including:

Meakins-Christie Laboratories logo

The Meakins-Christie Laboratories is one of the premier centres for pulmonary research in Canada, whose mission is to understand the pathobiology of respiratory disorders and to drive innovations in respiratory disease prevention, diagnosis, and therapy.

Respiratory Epidemiology and Clinical Research Unit (RECRU) logo

The Respiratory Epidemiology and Clinical Research Unit (RECRU) is a leading centre for epidemiological research, clinical trials, and economic analyses. It conducts clinical and community-based research studies.

McGill TB Centre logo

The McGill TB Centre is a world leader in the study of TB, bringing together research expertise in epidemiology, policy setting, economic analyses, implementation research, meta-analyses, qualitative research and basic science including microbiology, host genetics and immune response.

McGill Research Centre for Cannabis logo

The McGill Research Centre for Cannabis incorporates multidisciplinary research in plant science, production and processing, disease models and preclinical research, drug development and clinical trials, as well as social implications and health and economic impact studies.

Biobank of the Quebec Respiratory Health Research Network (RSRQ) logo

The Biobank of the Quebec Respiratory Health Research Network (RSRQ) is a common resource spread over several participating centers to provide high quality, well documented biological materials, essential for improving the understanding of respiratory disease.

MUHC COVID-19 Biobank logo

The MUHC COVID-19 Biobank is an integral part of the Biobanque québécoise de la COVID-19 (BQC), providing state-of the-art infrastructure and the research expertise required to collect, store and share biological samples and medical data from people infected with COVID-19.

McGill University Health Centre logo

The mission of the McGill University Health Centre Consortium for Rare Disease (MUHC-CRDR) is to facilitate patient-oriented, collaborative, trans-disciplinary healthcare and research in Rare Diseases across the lifespan.

CanCOLD is a collaborative Canada-wide study advancing knowledge of why people develop COPD, how and why COPD impacts individuals differently, and how to provide better care for people affected by this disease.

The McGill Centre for Microbiome Research supports microbiome research activities and outcomes to generate evidence-based knowledge for the benefit of medicine and public health.

Contact the RESP Program

Contact the RESP Program at the RI-MUHC. We are happy to hear from you!

Inga Murawski, PhD
Inga Murawski, PhD

Program Manager

Explore research at the RI-MUHC

Useful links

About the RI-MUHC

The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC.